Abstract
e16551Background: The mTOR inhibitor Everolimus (E) has shown to have clinical benefit and is a standard second-line treatment in advanced Renal cell carcinoma (RCC). Yet, there are notable toxicit...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
